6533b7cffe1ef96bd1259a22
RESEARCH PRODUCT
Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology
Luis Paz-aresAntonio ChellaG. Cuyun CarterEdward B. GaronAnnamaria ZimmermannM. TiseoVittorio GebbiaMaurice PérolAdolfo FavarettoOscar AlabisoLaura PizzutiMaria Rita MigliorinoP. BidoliPablo LeeFrederico Cappuzzosubject
Oncologymedicine.medical_specialtybusiness.industryHistologySubgroup analysisHematologyPlaceboStage IV non-small cell lung cancerSurgeryRamucirumabDouble blindSecond lineOncologyDocetaxelInternal medicinemedicinebusinessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2015-10-01 |